| Description | Bisacodyl (Fenilaxan) is a diphenylmethane stimulant laxative used for the treatment of constipation and for bowel evacuation. |
| In vitro | Bisacodyl抑制大鼠空肠,回肠和结肠的水分吸收,抑制程度与bisacodyl浓度的对数线性相关.4.3 mg/kg Bisacodyl与AOM联用增加大鼠体内每个集落小囊的数量,但是不增加肿瘤的数量.43 mg/kg Bisacodyl明显增加大鼠每个集落小囊和肿瘤的数量.与生理盐水处理的大鼠相比,Bisacodyl（5.9 mg/kg）显著降低空肠和结肠（Na + K）ATP酶活性.5.9 mg/kg Bisacodyl与对照组大鼠相比,明显增加空肠和结肠中PGE2含量,并刺激空肠和结肠腺苷酸环化酶的活性,且不影响cAMP含量.灌胃10 mg/kg Bisacodyl引起大鼠空肠NOS活性明显下降.20 mg/kg Bisacodyl导致大鼠结肠中AQP3蛋白质表达减少,而TNF-α的mRNA表达水平增加. |
| In vivo | 10 μg/mL Bisacodyl作用于Raw264.7细胞,增加TNF-α,COX2和PGE2的mRNA表达水平。 |
| Synonyms | 比沙可啶, Fenilaxan, Dulcolax, Brocalax |
| molecular weight | 361.39 |
| Molecular formula | C22H19NO4 |
| CAS | 603-50-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 55 mg/mL (152.19 mM), Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble) |
| References | 1. Ikarashi N, et al. Am J Physiol Gastrointest Liver Physiol, 2011, 301(5), G887-895. 2. Saunders DR, et al. Gastroenterology, 1977, 72(5 Pt 1), 849-856. 3. Karmeli F, et al. Scand J Gastroenterol, 1997, 32(8), 791-796. 4. Rachmilewitz D, et al. Dig Dis Sci, 1980, 25(8), 602-608. 5. Borrelli F, et al. Life Sci, 2001, 69(16), 1871-1877. |